Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00589875 · ClinicalTrials.gov registry record · Phase 2
Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma
A Phase 2 study, sponsored by Candel Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT00589875: Completed Phase 2 study, sponsored by Candel Therapeutics.
NCT00589875 is a Phase 2 study that has completed, run by Candel Therapeutics. The registered enrollment target is 52 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00589875, a Phase 2 study, has completed, sponsored by Candel Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the safety and potential efficacy of CAN-2409 (also known / previously described as AdV-tk, GMCI) for malignant gliomas. The approach used an adenoviral vector (disabled virus) engineered to express the Herpes thymidine kinase gene (aglatimagene besadenovec, CAN-2409), followed by an antiherpetic prodrug, valacyclovir. CAN-2409 was injected into the resection bed after standard tumor surgery and valacyclovir pills were taken for 14 days. Standard radiation and chemotherapy were administered which have been shown to work cooperatively with CAN-2409 + prodrug to kill tumor cells. The hypothesis is that this combination therapy can be safely delivered and will lead to improvement in the clinical outcome for patients with newly diagnosed malignant gliomas, including glioblastoma multiforme (WHO grade IV) and anaplastic astrocytomas (WHO grade III).
Interventions
- DRUG Temozolomide
- RADIATION Radiation therapy
- DRUG Valacyclovir
- BIOLOGICAL CAN-2409
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2007-03 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
What the finished NCT00589875 record still lists
NCT00589875 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 4 interventions - of which Temozolomide is the first listed.
NCT00589875 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00589875 about?
NCT00589875 is a clinical study titled "Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma". The purpose of this study was to evaluate the safety and potential efficacy of CAN-2409 (also known / previously described as AdV-tk, GMCI) for malignant gliomas. The approach used an adenoviral vector (disabled virus) engineered to express the Herpes thymidine kinase gene (aglatimagene besadenovec,...
What is the current status of trial NCT00589875?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2007-03. Estimated completion is 2016-08.
What interventions are being tested in trial NCT00589875?
The interventions under investigation include: Temozolomide (DRUG), Radiation therapy (RADIATION), Valacyclovir (DRUG), CAN-2409 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00589875?
This trial is sponsored by Candel Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00589875's enrollment target sits among peer trials
52 1181st of 2000 higher than 811 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia